<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04259372</url>
  </required_header>
  <id_info>
    <org_study_id>Tmet_AML</org_study_id>
    <nct_id>NCT04259372</nct_id>
  </id_info>
  <brief_title>Analysis of T Cell Metabolism in Acute Myeloid Leukemia Patients</brief_title>
  <official_title>Analysis of T Cell Metabolism and Immune Phenotype During the Course of Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to analyze the T cell metabolism and immune phenotype in AML
      patients during the course of the disease before and after allo-HCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who experience relapse of acute myeloid leukemia (AML) after allogeneic
      hematopoietic cell transplantation (allo-HCT) have a dismal prognosis. Infusion of donor T
      cells can induce graft-versus-leukemia (GVL) effects, indicating the importance of intact T
      cell function for leukemia control. Recent studies have shown the importance of metabolic
      fitness for an effective T cell response.

      In this study we have analyzed the T cell metabolism and immune phenotype in AML patients at
      different time points before and after allo-HCT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>T cell metabolism</measure>
    <time_frame>4 years</time_frame>
    <description>Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) determined by live-cell metabolic assay using the Seahorse Analyzer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T cell phenotype</measure>
    <time_frame>4 years</time_frame>
    <description>T cell cytokine and effector molecule production</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolite abundance in serum</measure>
    <time_frame>4 years</time_frame>
    <description>Serum metabolites as measured by mass spectrometry</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">77</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Primary Diagnosis</arm_group_label>
    <description>Analysis of patient blood at primary diagnosis of AML</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relapse</arm_group_label>
    <description>Analysis of patient blood at time point of relapse after allo-HCT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remission</arm_group_label>
    <description>Analysis of patient blood during remission after allo-HCT</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with acute myeloid leukemia at primary diagnosis, at relapse after allo-HCT
        or in remission after allo-HCT.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed diagnosis of AML

          -  age ≥ 18 years

          -  peripheral blood sample available

          -  written informed consent

          -  ability to understand the nature of the study and the study related procedures and to
             comply with them

        Exclusion Criteria:

          -  age &lt; 18 years

          -  lack of informed consent

          -  patients that cannot be classified in one of the 3 groups
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Zeiser, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center University of Freiburg</affiliation>
  </overall_official>
  <reference>
    <citation>Buck MD, O'Sullivan D, Klein Geltink RI, Curtis JD, Chang CH, Sanin DE, Qiu J, Kretz O, Braas D, van der Windt GJ, Chen Q, Huang SC, O'Neill CM, Edelson BT, Pearce EJ, Sesaki H, Huber TB, Rambold AS, Pearce EL. Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming. Cell. 2016 Jun 30;166(1):63-76. doi: 10.1016/j.cell.2016.05.035. Epub 2016 Jun 9.</citation>
    <PMID>27293185</PMID>
  </reference>
  <reference>
    <citation>Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, Tonc E, Schreiber RD, Pearce EJ, Pearce EL. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015 Sep 10;162(6):1229-41. doi: 10.1016/j.cell.2015.08.016. Epub 2015 Aug 27.</citation>
    <PMID>26321679</PMID>
  </reference>
  <reference>
    <citation>Schmid C, Labopin M, Nagler A, Bornhäuser M, Finke J, Fassas A, Volin L, Gürman G, Maertens J, Bordigoni P, Holler E, Ehninger G, Polge E, Gorin NC, Kolb HJ, Rocha V; EBMT Acute Leukemia Working Party. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007 Nov 1;25(31):4938-45. Epub 2007 Oct 1.</citation>
    <PMID>17909197</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Freiburg</investigator_affiliation>
    <investigator_full_name>Robert Zeiser</investigator_full_name>
    <investigator_title>Director of the Division of Tumor Immunology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

